Research article
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
Susan J Cleator¹,², Trevor J Powles³, Tim Dexter¹, Laura Fulford¹, Alan Mackay¹, Ian E Smith⁴, Haukur Valgeirsson¹, Alan Ashworth¹ and Mitch Dowsett¹,⁵

¹Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, SW3 6JB, London, UK
²Current address: Department of Oncology, St. Mary’s Hospital, Praed Street, London W2 1NY, UK
³Parkside Hospital, Parkside, SW19 5NX, London, UK
⁴Breast Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
⁵Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, SW3 6JJ, London, UK

Corresponding author: Susan J Cleator, s.cleator@imperial.ac.uk

Received: 2 Oct 2005 Revisions requested: 10 Nov 2005 Revisions received: 6 Apr 2006 Accepted: 26 May 2006 Published: 21 Jun 2006

Breast Cancer Research 2006, 8:R32 (doi:10.1186/bcr1506)
This article is online at: http://breast-cancer-research.com/content/8/3/R32
© 2006 Cleator et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction The aim of this study was to examine the effect of the cellular composition of biopsies on the error rates of multigene predictors of response of breast tumours to neoadjuvant adriamycin and cyclophosphamide (AC) chemotherapy.

Materials and methods Core biopsies were taken from primary breast tumours of 43 patients prior to AC, and subsequent clinical response was recorded. Post-chemotherapy (day 21) samples were available for 16 of these samples. Frozen sections of each core were used to estimate the proportion of invasive cancer and other tissue components at three levels. Transcriptional profiling was performed using a cDNA array containing 4,600 elements.

Results Twenty-three (53%) patients demonstrated a 'good' and 20 (47%) a 'poor' clinical response. The percentage invasive tumour in core biopsies collected from these patients varied markedly. Despite this, agglomerative clustering of sample expression profiles showed that almost all biopsies from the same tumour aggregated as nearest neighbours. SAM (significance analysis of microarrays) regression analysis identified 144 genes which distinguished high- and low-percentage invasive tumour biopsies at a false discovery rate of not more than 5%. The misclassification error of prediction of clinical response using microarray data from pre-treatment biopsies (on leave-one-out cross-validation) was 28%. When prediction was performed on subsets of samples which were more homogeneous in their proportions of malignant and stromal cells, the misclassification error was considerably lower (8%–13%, p < 0.05 on permutation).

Conclusion The non-tumour content of breast cancer samples has a significant effect on gene expression profiles. Consideration of this factor improves accuracy of response prediction by expression array profiling. Future gene expression array prediction studies should be planned taking this into account.

Introduction Breast tumours are routinely subclassified according to microscopic morphology, immunohistochemical staining, and stage. On the basis of this clinical information and patient age, an estimate of prognosis may be derived [1,2]. Most clinicians make recommendations regarding the need for adjuvant chemotherapy on the basis of this estimate. However, breast cancer is a heterogeneous disease, and differences in prognosis and response in distinct molecular subgroups need to be taken into account. Improvement in the accuracy of prediction of prognosis without systemic treatment or with endocrine treatment alone would allow avoidance...
of non-beneficial chemotherapy in a significant proportion of women [3]. Additionally, experience with neoadjuvant che-
mo therapy has demonstrated resistance in a significant propor-
tion of primary breast tumours [4]. These patients derive no
downstaging benefits from neoadjuvant chemotherapy. Fur-
thermore, chemosensitivity in the neoadjuvant setting is asso-
ciated with superior long-term survival (relative to chemoresistance) [5] and therefore may represent a marker of
survival benefit from chemotherapy. Identification of a chem-
oresistant profile would allow further tailoring of treatment by
enabling selection of tumours unlikely to respond and there-
fore unlikely to derive a survival benefit.

Several studies have demonstrated that gene expression
microarray profiling may be useful in improving prediction of
prognosis [6-9] and treatment response [10-16]. These stud-
ies employed non-dissected surgical [7-9], core-cut biopsy
[12], or FNA (fine needle aspiration) samples [10]. However,
breast tumours are non-homogenous in nature. They include
inflammatory and vascular elements but most significantly (by
proportion) connective tissue components [17]. The propor-
tions of these components vary according to tumour type and
sample type and also across a single tumour [17]. In studies
involving surgical samples, those used for profiling can be
selected as those with the highest proportional malignant cell
content. In studies involving biopsies, this is not possible and
the researcher is required to set an arbitrary minimum percent-
age tumour limit.

The impact on expression profile of variation in the proportion
of tumour cells and the nature of the non-tumour components
have been largely unexplored. In this paper, we examine the
effect of percentage tumour content on expression profile
within a study designed to derive an expression profile predic-
tive of response to adriamycin and cyclophosphamide (AC)
neoadjuvant chemotherapy. We also consider methods for
improvement of molecular profile-based prediction of
response to primary chemotherapy by classification of sam-
ple according to cellular makeup or by the incorporation of
sample tumour content information into the predictor.

Materials and methods
Patients and samples
Patients were recruited and treated at the Royal Marsden Hos-
pital (RMH), London, UK. Eligible patients were those under-
going neoadjuvant AC chemotherapy treatment at doses of 60
and 800 mg/m², respectively, three times a week, for a cli-
nically measurable breast tumour. The study was approved by
the RMH Clinical Research and Ethics Committees (study number. 1,947), and written consent was obtained in all
cases. Patients had been allocated neoadjuvant treatment for
one of several standard indications, including locally advanced
or inflammatory breast cancer, high tumour-to-breast size ratio,
and tumours located close to the nipple.

Diagnosis was confirmed histologically by core-cut biopsy. All
patients on hormone replacement therapy at diagnosis were
advised to discontinue this treatment. Patients who demon-
strated at least a partial clinical response received six cycles
of treatment prior to local treatment. Patients in whom there
was no or only marginal response after three or four cycles
proceeded directly to local treatment or were commenced on
alternative systemic treatment (docetaxel).

Clinical size of tumour (largest diameter and a diameter per-
pendicular to this) was recorded prior to commencement and
at completion of treatment. Clinical response was categorised
as follows: no palpable abnormality after treatment, complete
clinical response (cCR); more than 50% reduction in the pro-
duct of the bidimensional measurements, partial response (PR);
less than 50% reduction in the product of bidimensional meas-
urements was recorded as no change (NC); and residual ill-
defined thickening after a good response, minimal residual dis-
ease (MRD). Those cases in which there was no residual inva-
sive carcinoma at surgery were classified as a complete pat-
ological response (pCR). Good responders were defined as
pCR, cCR, or MRD; poor responders were defined as PR
or NC. These categories were chosen on the basis of our pre-
vious study, which showed that patients with ‘good’ response
had superior overall survival relative to those with ‘poor’
response [18]. A proportion of patients undergoing a com-
plete clinical and radiological (on ultrasound) response
received radiation only as local treatment. Therefore, some of
the cCRs may represent undocumented pCRs.

Research 14-gauge core biopsies were collected prior to
commencing treatment and snap-frozen in liquid nitrogen.
When consented to, a repeat sample was taken at 21 days
after the first cycle of chemotherapy. All samples were there-
after coded using a study number as an identifier. Frozen
cores were embedded in OCT (optimum cutting temperature
embedding compound) and sectioned at -20°C in a cryostat.
Sections (5 µm in thickness) were taken for haematoxylin and
eosin staining to assess histological character superficially
from the core as soon as ‘full-face’ was reached. The percent-
age of cells comprising invasive malignant disease and non-
malignant components (that is, in situ disease, inflammatory
infiltrate, non-malignant ductal/lobular structures, and fibrob-
lastic involvement) were recorded by consensus between two
breast pathologists. For patients in whom multiple biopsies
were available, the biopsy with the highest invasive content
was used for microarray analysis. Biopsies with less than 20%
invasive cancer content were excluded from the study.

RNA extraction and amplification
Cores were extracted from OCT as described by Ellis and col-
leagues [19] and pulvursed using a pestle and mortar on a bed
of dry ice and subsequently in 1 ml of Trizol reagent (Invitro-
gen, Carlsbad, CA, USA) with a ‘Polytron’ homogenizer.
Standard ‘Trizol’ RNA extraction was carried out without use
of a carrier according to the manufacturers’ instructions. Samples not giving distinct 18S and 28S peaks on an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) trace were excluded from the study. Multiple cores from the same patient were handled separately for RNA extraction. A single round of T7 linear RNA amplification was carried out using the RiboAmp kit (Arcturus, Sunnyvale, CA, USA) with a starting amount of 1 µg when available or 50% of the available RNA.

Reference RNA was generated from a pool of RNAs extracted from 20 independent breast cancer surgical samples.

cDNA array hybridisation
Microarray analyses used in-house (Breakthrough Breast Cancer Research Centre, London, UK) human arrays spotted with DNA derived from 4,600 IMAGE cDNA clones in duplicate. This set of genes represents a subset of the 5,808 Cancer Research UK (London, UK) gene set that was designed to include a high proportion of genes documented as being involved in carcinogenesis or tumour biology. To improve ‘coverage’ of genes involved in breast cancer, a list of discriminatory genes cited in important microarray studies on clinical breast cancer samples at time of production was compiled [7,20-22], and the array was supplemented with these. One

| Table 1  |  
| Patient, tumour, and pre-treatment biopsy characteristics (43 samples used in prediction analysis)  |  
| Age: median (range)  | 49 (28–68)  
| Menopausal status  |  
| pre: 25 (58%)  |  
| post: 9 (21%)  |  
| na: 1 (2%)  |  
| HRT: 8 (19%)  |  
| Histological subtype  |  
| lob: 6 (14%)  |  
| duct: 34 (79%)  |  
| duct/lob: 1 (2%)  |  
| medull: 1 (2%)  |  
| na: 1  |  
| ER status  |  
| +: 29 (67%)  |  
| -: 13 (30%)  |  
| na: 1 (2%)  |  
| HER-2 status  |  
| +: 5 (12%)  |  
| -: 36 (84%)  |  
| na: 2 (5%)  |  
| Inflamm infiltrate  |  
| nil: 19 (44%)  |  
| mild: 16 (37%)  |  
| mod: 6 (14%)  |  
| severe: 2 (5%)  |  
| Grade  |  
| 2: 18 (42%)  |  
| 3: 24 (56%)  |  
| na: 1 (2%)  |  
| Percentage invasive tumour: median (range)  | 50 (20–95)  
| Response  |  
| pCR: 4 (9%)*  |  
| cCR: 16 (37%)  |  
| MRD: 3 (7%)  |  
| PR: 8 (19%)  |  
| NC: 12 (28%)  |  
| Clinical stage:  |  
| Primary dimension (n)  | 2.0–3.0 cm  | 15  
| 3.1–4.0 cm  | 7  
| 4.1–5.0 cm  | 9  
| >5.0 cm  | 11  
| Multifocal  | 1  
| Median dimension (range) (cm)  | 4 (2–10)  
| Skin involvement (n)  | 2  
| HER2 +  | 4 (10%)  
| 1 (2%)  |  
| Inflammatory (n)  | 2  
| HER2 -  | 24 (56%)  
| 12 (28%)  |  
| Nodal involvement (n)  | N0  | 29  
| N1  | 14  
| N2  | 0  
| NA  | 0  

*Postmenopausal’ refers to patients not on HRT at diagnosis. Postmenopausal patients on HRT at diagnosis are listed under ‘HRT’. ‘Primary dimension’ refers to the maximum tumour diameter (cm). ‘Inflammatory infiltrate’ score and ‘median percentage invasive tumour’ relate to values for the core used in prediction analysis. +, positive; -, negative; cCR, complete clinical response; duct, ductal; duct/lob, mixed ductal/lobular carcinoma; ER, oestrogen receptor; HRT, hormone replacement therapy; lob, lobular; medull, medullary; inflamm, inflammatory; mod, moderate; MRD, minimal residual disease; na, not available; NC, no change; pCR, complete pathological response; PR, partial response.
## Table 2

**SAM (significance analysis of microarrays) analysis of genes correlated to percentage tumour content.**

| Gene name | Genbank accession | Unigene cluster ID | Symbol | Score (d) | q-value (%) |
|-----------|-------------------|--------------------|--------|-----------|-------------|
| ADP-ribosylation factor 1 | AK023803 | Hs.286221 | ARF1 | 3.11 | 4.13 |
| CDC28 protein kinase regulatory subunit 2 | B0898943 | Hs.83758 | CKS2 | 2.73 | 4.13 |
| TRK-fused gene | NM_006070 | Hs.446568 | TFG | 2.65 | 4.13 |
| Discs, large homolog 7 (Drosophila) | NM_014750 | Hs.77695 | DLG7 | 2.60 | 4.13 |
| RAB6B, member RAS oncogene family | NM_016577 | Hs.352530 | RAB6B | 2.59 | 4.13 |
| Epithelial cell transforming sequence 2 oncogene | CR749278 | Hs.528300 | PSTRM1 | 2.46 | 4.13 |
| FXYD domain containing ion transport regulator 2 | CR827143 | Hs.413137 | FXYD2 | 2.54 | 4.13 |
| Ubiquitin specific protease 9, X-linked (fat facets-like, Drosophila) | NM_004652 | Hs.77578 | USP9X | 2.48 | 4.13 |
| Pitrilysin metalloproteinase 1 | CR749278 | Hs.528300 | PSTRM1 | 2.46 | 4.13 |
| Myeloid differentiation primary response gene (88) | AK124685 | Hs.82116 | MYD88 | 2.44 | 4.13 |
| Baculoviral IAP repeat-containing 5 (survivin) | NM_001012271 | Hs.1578 | BIRC5 | 2.42 | 4.13 |
| Polo-like kinase 4 (Drosophila) | NM_014264 | Hs.172052 | PLK4 | 2.40 | 4.13 |
| 2',3’-cyclic nucleotide 3’ phosphodiesterase | NM_033133 | Hs.443836 | CNP | 2.40 | 4.13 |
| Triosephosphate isomerase 1 | NM_013099 | Hs.83848 | TPI1 | 2.39 | 4.13 |
| ALL1-fused gene from chromosome 1q | BX649117 | Hs.75823 | AFIQ | 2.37 | 4.13 |
| Latent transforming growth factor beta binding protein 2 | NM_004288 | Hs.105869 | LTBP2 | -3.40 | 1.00 |
| LIM domain binding 2 | AL832772 | Hs.4980 | LDB2 | -3.43 | 1.00 |
| Collagen, type XV, alpha 1 | NM_0010456 | Hs.409034 | COL15A1 | -3.39 | 1.00 |
| Cadherin 5, type 2, VE-cadherin (vascular epithelium) | NM_001795 | Hs.76206 | CDH5 | -3.30 | 1.00 |
| Forkhead box O1A (rhabdomyosarcoma) | NM_002015 | Hs.170133 | FOXO1A | -3.17 | 1.00 |
| TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous) | BC035514 | Hs.89640 | TEK | -3.02 | 1.00 |
| Regulator of G-protein signaling 5 | NM_003617 | Hs.24950 | RGS5 | -2.97 | 1.00 |
| Fasciculation and elongation protein zeta 1 (zygin I) | NM_022549 | Hs.79226 | FEZ1 | -2.90 | 1.00 |
| Vascular endothelial growth factor C | NM_005429 | Hs.79141 | VEGFC | -2.90 | 1.00 |
| Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain | NM_003841 | Hs.253829 | TNFRSF10C | -2.82 | 1.00 |
| CDNA FLJ25106 fis, clone CBR01467 | AK128814 | Hs.432914 | -2.79 | 1.00 |
| Alpha-2-macroglobulin | CR749334 | Hs.74561 | A2M | -2.77 | 1.00 |
| Meis1, myeloid ecotropic viral integration site 1 homolog 2 (mouse) | NM_170677 | Hs.362805 | MEIS2 | -2.71 | 1.00 |
| Tropomodulin 1 | AK096156 | Hs.404289 | TMOD1 | -2.70 | 1.00 |
was determined as suggested by Radmacher and colleagues [27]. In this procedure, the LOOCV estimate was determined 1,000 times for permuted class labels; the fraction of these that gave an equal or lower error estimate than that with true labels is taken as the p value. We refer to the latter as a 'label permutation'.

To assess the significance of lower misclassification error estimates for selected subsets of the samples, we needed to control for the smaller sample sizes. To this end, we defined a 'subset permutation' p value as the fraction of random subsets (1,000 matched for size and class proportions) of the full set of samples that gave rise to LOOCV error estimates equal to or lower than the selected subset. The correct class labels were used for subset permutation. The minimum error for each permutation across the top 2 to 10 ranked genes was used to calculate the p values for both of the above types of permutation to avoid bias. Although this is an arbitrary range, the minimum error rates in all the permutations had increased by a cutoff of 10. Significance analysis of microarrays (SAM) analyses were performed using standard software [29]. Pre-treatment samples only were used for prediction analyses.

### Results

**Patient and tumour characteristics**

RNA of adequate amount and quality was available from 43 tumours before treatment. Of these, 23 (53%) demonstrated a 'good' and 20 (47%) a 'poor' clinical response. For 16 of these tumours, a paired 21-day sample was also available. These 'on treatment' biopsies are included in the analysis of reproducibility shown below to increase the number of paired samples but are excluded from the analysis of response prediction. The good responses comprised 16 (37%) that underwent a cCR, three (7%) that exhibited ill-defined thickening (MRD) at the end of treatment, and four (9%) that underwent a pCR (all cCR or MRD). The patient and tumour characteristics are shown in Table 1. The only feature differing between good and poor responders was tumour size, with pre-treatment size greater in poor compared with good responders (Mann-Whitney, p = 0.03). Pre-treatment size did not relate to expression profile (data not shown).

**Biopsy characteristics**

A total of 147 cores were sectioned in the course of this study, including 104 that were sectioned at three levels (levels approximately 50 μm apart). Of these 104 cores, only 16 cores showed more than 10% absolute variation in invasive tumour content across all three sections and only one core showed more than 20% variation. Only four cores were found

| ISOLEUCINE-TRNA SYNTHETASE | NM_013417 | Hs.172801 | IARS | -2.63 | 1.00 |
|-----------------------------|-----------|-----------|------|-------|------|

Positive values for score (bold) indicate positive correlation with percentage tumour, and negative values indicate inverse correlation with percentage tumour (underlined). The table has been truncated to show only genes with the lowest false discovery rates (q).
to have tumour at some levels and none at others; all four contained not more than 15% invasive tumour at the lowest level and were therefore excluded from the study. This suggests that the histological composition did not vary widely over the width of the core. The histological result from the lowest section for a given biopsy was taken as that most representative of the remaining biopsy used for profiling and hence the level on which percentage invasive tumour was assessed. The distribution of percentage invasive content of core (in cases of multiple cores, that core used for prediction analysis) did not relate to response as assessed by Wilcoxon rank sum test ($p = 0.3$) or $t$ test ($p = 0.27$).

Percentage invasive content in core biopsies included in the prediction study varied from 20% to 95% (median 50%). For most core biopsies, the majority of the non-malignant tissue consisted of connective tissue. Inflammatory infiltrate was also scored on the lowest section as nil, mild, moderate, or severe. Of all 147 core biopsies, only six (4%) were scored as having a 'severe' inflammatory infiltrate at one or more levels.

### Table 3

| Set of samples           | Sample size | Minimum error rate | $n$ of genes used in predictor | $p$ value on 'subset' permutation | $p$ value on 'label' permutation |
|-------------------------|-------------|--------------------|-------------------------------|----------------------------------|---------------------------------|
| All (20%–90%)           | 43          | 28%                | 3                             | Not determined                   | 0.079                           |
| High range (50%–95%)    | 25          | 12%                | 4                             | 0.026                            | 0.021                           |
| Low range (20%–50%)     | 24          | 13%                | 7                             | 0.039                            | 0.028                           |
| Mid range (35%–60%)     | 24          | 8%                 | 7                             | 0.001                            | 0.002                           |

Column 1 shows the division of samples into three groups according to percentage invasive tumour content. Details of minimum error predictors for all samples and subsets. Permutation $p$ values were calculated as described in Materials and methods.

### Basic validation of array data

To assess consistency of the expression profile between repeated biopsies, the 43 pre-treatment and 16 paired post-treatment samples were clustered (Additional file 1). The post-treatment samples were included in this validation study only to enhance numbers and were not used in subsequent predictive analyses. All but one pair (b223A and B) of duplicate biopsies taken at the same time point relative to treatment (in total, five pre-treatment and five post-treatment pairs) clustered as nearest neighbours despite some variation in percentage tumour between the pairs (Additional file 3). Of 16 pre/post-treatment pairs, 14 clustered with samples from the same tumour (Additional file 1). To validate our class prediction methodology, a supervised analysis was undertaken to obtain a gene list for prediction of oestrogen receptor (ER) status in pre-treatment samples (ER-$\alpha$ was excluded from the analysis). ER status was correctly assigned in 40 of 42 cases on LOOCV. Discriminatory genes are listed in the supplementary information (Additional file 4).
Effect of percentage tumour on expression profile

Before performing prediction analysis, an exploratory analysis was undertaken to assess the impact of variation in the histological content of biopsies on the expression profile. A SAM...
regression analysis was performed to establish whether it was possible to identify genes that correlated with the proportion of tumour cells in the 43 pre-treatment core biopsies. One hundred forty-four genes were significant at a false discovery rate of not more than 5%. Table 2 shows the most correlated genes from this analysis. Positive values for ‘score’ (bold) indicate positive correlation with high percentage tumours, and negative values (underlined) indicate negative correlation with proportion of tumour cells in the samples. More genes correlated positively with the stromal content \((n = 128)\) than with the tumour content \((n = 16)\), possibly reflecting the greater molecular heterogeneity of tumour types across the samples than that of their associated stromas. This is also reflected in the higher false discovery rates for ‘tumour-associated genes’.

**Response prediction using pre-treatment biopsies**

Prediction analysis was initially undertaken on the full set of 43 biopsies. The optimum misclassification error estimate (LOOCV) for the whole sample set was 28% using a three-gene predictor (Figure 1). To explore the effect of biopsy tumour content (and its associated influence on the expression profile) on error of response prediction, we selected three overlapping subsets of tumour samples which were more homogeneous in terms of percentage tumour content: \((a)\geq 50%\) (50%–95% invasive tumour (25 samples), \((b)\leq 50%\) (20%–50%) invasive tumour (24 samples), and \((c)\) 35%–60% invasive tumour (24 samples).

The subset consisting of 35%–60% represented a group centered around the median sample in terms of percentage tumour content and of a size similar to or the same as the other two groups.

The minimum error of classification for each of the subsets (8%–13%) was lower than that for the superset of all samples (28%) (Figure 1), suggesting that homogeneity of tumour content rather than tumour content per se might be an important factor for response prediction. However, the comparison of the subset error estimates with that for all samples is not controlled for the different sample sizes involved. To address this, we determined a ‘subset permutation’ \(p\) value for each of the subsets (see Materials and methods). We also estimated the probability that the subset errors arose by chance (a 'label permutation' as discussed in Materials and methods). Error estimates and corresponding \(p\) values for the 'subset permutation' and the 'label permutation' support the hypothesis that homogeneity of biopsy tumour content improves response prediction with the nearest neighbour algorithm (Table 3). The identity of the genes used in the prediction for each of these subgroups is presented in Table 4. The mean differential expression between good and poor responders for these genes is given in the supplementary information (Additional file 5).

We found, in common with other studies [20,22,30-32], that ER-positive and ER-negative tumours were very distinct in molecular terms (Additional file 4), which may confound response prediction. Therefore, response prediction was performed on ER-positive samples alone (16 good, 13 poor responders). Error rates, however, were high (31% with 8 genes, 31% with 25 genes). Within this subset, the effect of heterogeneity of tumour content on prediction appeared to be more pronounced (error rates: 31% (all samples, \(n = 29\)) versus 4.5% \(\leq 60%\) tumour, \(n = 22\)).

**Incorporation of histological information into the predictor**

To explore further the effect of biopsy composition on prediction error, we attempted to create a single predictor for all samples by adding information about tumour content to the predictor as an extra dimension or 'histology gene'. The impact of variation in biopsy tumour content on prediction error was thought to be due partly to the fact that genes that discriminate between good and poor responders in high-tumour-content biopsies are often poor discriminators in low-tumour-content biopsies (and vice versa) as is evident from Table 4. To overcome this complication, 10 genes were selected that showed 100% support in the subset permutations (Table 4). By adding the proportion of tumour content to these 10 genes as an 11th dimension, we aimed to move the samples apart in 'prediction space' such that differences in tumour content also contributed to the distances between samples. Thus, samples with similar expression profiles become nearest neighbours of similar proportion of tumour content as well. In the nearest neighbour predictor, like is matched with like in terms of proportion of tumour content as well as expression profile.

It was necessary to rescale the histology gene’s contribution to the distance between samples because the standard deviation of most genes lay between 0.5 and 1.5 (log2 ratio scale). Therefore, the percentage tumour figures were standardised by subtracting the average and dividing by the standard deviation. The 'histology gene' or 11th dimension was then rescaled from 0 to 4 standard deviations, and the effect on cross-validation error determined (Figure 2). After an initial drop in error, as the scale approached 1.0, the error rose beyond the initial error as the influence of the histology gene became too dominant. To test whether the effect of the histology gene was specific to the particular set of 10 genes used above, we tested the effect of adding the histology gene to 1,000 predictors, each containing a random permutation of between 8 and 16 genes drawn from the top 20 genes ranked by a combined score (Additional file 6 a-c). In 91% of these, the addition of the histology gene resulted in a lower error; in 49%, the error drop was greater than 10%.

**Discussion**

In this study, we set out to explore the possibility that the transcriptional profile(s) of breast tumours relates to sensitivity to
neoadjuvant chemotherapy. Such a profile might be useful in understanding the molecular mechanisms determining response or resistance and would provide the basis for a predictor of chemotherapy response.

However, the biopsy material used in this study had a complex cellular composition. In planning this study, consideration had been given to two approaches for ensuring that the percentage invasive tumour within biopsies was 'sufficient' and homogeneous. Cell selection, either by gross dissection or laser capture microdissection [33], allows enrichment of the invasive tumour component. We chose, in common with others [6,7,11,13,14,31], to set a minimum threshold for 'percentage malignant cells' within a given biopsy. The median percentage invasive tumour for the core biopsy samples was 50%, and the range of figures that were included in the study was 20% to 95%. In many biopsies, the dominant non-tumour component, connective tissue, was admixed with epithelial components, making enrichment of the malignant compartment difficult using gross dissection alone.

We hypothesised that this 'contamination' of biopsies by significant and variable amounts of non-tumour components might confound tumour classification. Indeed, at least 10% of the genes (144 genes) remaining after preprocessing of the data were found to correlate with cellular composition using a SAM regression analysis. Genes relatively overexpressed in low-percentage tumours included established stromal-related genes (Table 2) (for example, Collagen (type XV, alpha-1) and Cadherin 5 (type 2, VE-cadherin)). The exact source (histological compartment) of production of a given RNA could be further confirmed by FISH (fluorescent in situ hybridisation) or by comparing gene expression in microdissected stromal and tumour compartments.

However, paired biopsies, despite differences in proportional non-tumour content (Additional file 3), co-aggregated on cluster analysis (Additional file 1), suggesting a dominant 'tumour profile' despite variation in the proportion of stroma. Furthermore, prediction of ER status was not confounded by marked variation in percentage tumour content. This is in keeping with a number of studies that have shown that strong differential variation in percentage tumour content. This is in keeping with whole sample set was poor (28%) but was improved by increasing the homogeneity of cellular composition by subsetting on the basis of histological composition (error rate, 8%–13%) (Table 3). The misclassification rates for the subsets were determined with LOOCV and therefore represent high variance estimates, and the sample numbers are modest. We have used permutation analysis as support for the error estimates; ultimately, however, validation with an independent data set would address these issues.

We did not find any evidence to suggest that highly stromal biopsies result in higher prediction error. However, stromal-tumour content appears to affect the selection of genes that are used in the predictor for each histological subset, resulting in different but overlapping lists of predictive genes (Table 4). Some genes discriminated response in the 'high percentage' and not the 'low percentage' samples (for example, PBEF1). This may simply be a dose effect whereby discriminatory tumour-associated genes are no longer differential in 'low percentage samples' due to low signal. Alternatively, discriminatory genes that are expressed in both tumour and non-tumour compartments may lose discriminatory potential in tumours with a significant stromal contribution to the molecular signature. Genes that are discriminatory in low but not high 'percentage samples' (for example, SOD1) could be expressed only at the tumour-stroma interface in stromal and/or tumour cells. Certainly, breast tumour-induced changes in stromal expression have been previously documented [34]. Furthermore, it has been shown that tumour gene upregulation can occur specifically at the tumour-stroma interface [35,36]. Finally, it is also likely that the volume and configuration of stromal tissue within a tumour are a reflection of the tumour molecular subtype.

Thus, this analysis resulted in three distinct response-prediction genes lists that partially overlapped. PBEF, reported in one study to act as an inhibitor of apoptosis in neutrophils [37], appeared in the predictor for response for 'high percentage' tumours and has also been reported as a component of a three-gene predictor of AC sensitivity by another group [13]. In both studies, expression of this gene was higher in the resistant tumours than in sensitive tumours. SOD1 was found to be relatively overexpressed in resistant tumours ('low' and 'mid percentage') in keeping with a proposed role in the neutralisation of free radicals, one means by which anthracyclines are thought to inflict cellular damage [38]. NDRG1, upregulated in poor responders ('high percentage'), is induced by hypoxia and may reduce p53 expression [39]. Hypoxia may be a marker of poor vascularisation of tumours and therefore possible limitation of drug access.

Although here we have defined histological subsets, we have shown that it might be feasible to build a predictor that extracts information about the cellular composition of the biopsy from expression data. We found that adding standardised percentage tumour values as a 'histology gene' (Figure 2) to multigene predictors (Table 4) reduced the error rate significantly, supporting the idea that it may be possible to devise a predictor...
that operates regardless of biopsy composition. This would avoid the need for microdissection to enrich for malignant cells. Furthermore, if stromal or stromal-interface gene expression does carry discriminatory information, then microdissection would result in loss of predictive information.

Several groups have attempted to define a multigene predictor of chemoresponsiveness [10-15], using either clinical or pathological definitions of response. The reported error rates in these studies, as assessed on an independent data set or by LOOCV, range from 5% to 30%. Comparison of gene lists and error rates across these studies and with ours is hampered by the fact that the treatment regimens, response definitions, and microarray platforms differ and that the histological composition of the samples in most studies was not presented.

A number of samples used in our study have also been profiled using an Affymetrix platform (Santa Clara, CA, USA) [40]. In this independent analysis, 12 samples from tumours displaying either cCR or pCR and six samples from tumours with residual tumour greater than 70% were used to define a classifier (samples with less than 40% tumour were excluded from the study). The error rate of prediction on LOOCV was 33% ($p = 0.4$ on permutation).

Therefore, to date, the reported error rates associated with expression array prediction of response, certainly for anthracycline combination chemotherapy, remain too high for clinical utility. This may be due in part to the fact that breast cancer is an extremely complex and heterogeneous disease that operates multiple mechanisms of chemotherapeutic response and resistance which are not consistent across different subtypes, particularly in the case of combination regimens incorporating agents that act by multiple mechanisms. Such complexities mandate that study designs be optimised in terms of biopsy quality and sample size.

**Conclusion**

The response prediction using all pre-treatment biopsies was modestly effective. However, the percentage of invasive cancer cells within a sample influenced the expression profile. Response prediction on subsets of samples more homogeneous in terms of cellular composition was associated with lower error rates. We believe that it is essential that consideration be given to biopsy composition in planning future studies of this type using methods such as those discussed above. Larger studies are required to establish whether optimal accuracy of response prediction may be achieved by the development of profiles specific to immunohistochemical breast cancer subtypes.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

SC was involved in design of study, acquisition of data, analysis and interpretation of results, and drafting the manuscript and preparing the final version (Breakthrough Breast Cancer Research Centre). TP participated in data acquisition and the conception and design of the study (RMH). TD was involved in analysis and interpretation of results, and drafting the manuscript and preparing the final version (Breakthrough Breast Cancer Research Centre). LF contributed to data acquisition (Breakthrough Breast Cancer Research Centre). AM performed data acquisition and analysis (Breakthrough Breast Cancer Research Centre). IS participated in data acquisition (RMH). HV performed data analysis (Breakthrough Breast Cancer Research Centre). AA participated in the design of study, interpretation of results, and preparing the final version of the manuscript (Breakthrough Breast Cancer Research Centre). MD was involved in the conception and design of the study, interpretation of results, and preparing the final version of the manuscript (RMH). All authors read and approved the final manuscript.

**Additional files**

The following Additional files are available online:

**Additional file 1**

A PDF file containing a dendrogram of flexible beta clustering with Spearman rank correlation on all core biopsy samples taken from 43 patients. See [http://www.biomedcentral.com/content/supplementary/bcr1506-S1.pdf](http://www.biomedcentral.com/content/supplementary/bcr1506-S1.pdf)

**Additional file 2**

A word document containing the legend for additional data file 1. See [http://www.biomedcentral.com/content/supplementary/bcr1506-S2.doc](http://www.biomedcentral.com/content/supplementary/bcr1506-S2.doc)

**Additional file 3**

A word document containing a table that shows the characteristics of paired (repeat) core biopsy samples. See [http://www.biomedcentral.com/content/supplementary/bcr1506-S3.doc](http://www.biomedcentral.com/content/supplementary/bcr1506-S3.doc)

**Additional file 4**

A word document containing a table that shows the oestrogen receptor (ER) predictive genes. See [http://www.biomedcentral.com/content/supplementary/bcr1506-S4.doc](http://www.biomedcentral.com/content/supplementary/bcr1506-S4.doc)

**Additional file 5**

A word document containing a table that shows response prediction gene lists with expression ratios. See [http://www.biomedcentral.com/content/supplementary/bcr1506-S5.doc](http://www.biomedcentral.com/content/supplementary/bcr1506-S5.doc)
Acknowledgements

We thank Kerry Fenwick, Peter Kerr, Sunil Lakhani, and Marjan Iravani (all of whom were funded by the Breakthrough Breast Cancer Research Centre) and Margaret Hill and Geraldine Walsh (who were funded by RMH). The study and the manuscript preparation were funded by the Breakthrough Breast Cancer Research Centre. Neither of the above funding body in the writing of the manuscript or the decision to submit it.

References

1. Galea MH, Blayney RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
2. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris JD, Davis GJ, Chia SK, Gomelova K: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2003, 21:3716-3725.
3. Cleator S, Ashworth A: Molecular profiling of breast cancer: clinical implications. Br J Cancer 2004, 90:1120-1124.
4. Fisher B, Brown A, Mamounas E, Weiand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. Clin Oncol 1997, 15:2483-2493.
5. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;98:102.
6. Sotiriou C, Neo SY, McShane LM, Kom EL, Long PM, Jazera A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
7. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
8. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber DJ, Peterse JL, Roberts C, Marton MJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
9. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
10. Ayers M, Symmans WF, Stec J, Damkoehler AI, Clark E, Hess K, Lecocke M, Mettivier J, Booser D, Ibrahim N, et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22:2284-2293.
11. Bertucci F, Finetti P, Rougmont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerio J, Taggett R, Tarpin C, Houvenaeghel G, et al.: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004, 64:8556-8565.
12. Chang JC, Wooten EC, Tamatson A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Channess GC, Allred DC, O’Connell P: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362:262-269.
13. Folgueira MA, Carrano DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, et al.: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005, 11:7434-7443.
14. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005, 23:3311-3316.
15. Iwao-Kozumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23:422-431.
16. Madisch O, Prischack H, Munzen S, Audretsch W, Bojar H: Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 2005, 3:32.
17. WHO: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Genital Organs: IARC Press; 2003.
18. Cleator S, Makris A, Ashley SE, Lal R, Powles TJ: Good clinical response of breast cancers to neoadjuvant chemoendocrine treatment is associated with improved overall survival. Ann Oncol 2005, 16:267-272.
19. Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanth S, Zhou S, Schumacher B, Wallach DM, et al.: Expression patterns. Breast Cancer Res 2002, 2:155-166.
20. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001, 61:5979-5984.
21. Sotiriou C, Powles TJ, Dowsett M, Jazaery AA, Feldman AL, Assersohn L, Gadietski C, Libutti SK, Liu ET: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002, 2:R3.
22. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevin Jr: Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001, 98:11462-11467.
23. Dudoit S: Statistical methods for identifying differentially expressed genes in replicated CDNA microarray experiments. Statistica Sinica 2002, 12:111-139.
24. Everitt BS: Cluster Analysis London: Arnold; 1993.
25. Lancé G, Williams W: A general theory of classification sorting strategies: Hierarchical systems. Computer Journal 1967, 9:373-380.
26. Dudoit S, Fridyday J: Classification in microarray experiments. In Statistical Analysis of Gene Expression Data Edited by: Speed T. Boca Raton: Chapman and Hall/CRC; 2003.
27. Wilcox R: Introduction to Robust Estimation and Hypothesis Testing San Diego: Academic Press; 1997.
28. Radmacher MD, McShane LM, Simon R: A paradigm for class prediction using gene expression profiles. J Comput Biol 2002, 9:505-511.
29. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121.
30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al.: Gene expression patterns of breast carcinomas distinguish tumor sub-
classes with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
31. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
32. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
33. Sgroi DC, Teng S, Robinson G, LeVangie R, Hudson JR Jr, Elkahlow AG: In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 1999, 59:5656-5661.
34. Iacobuzio-Donahue CA, Argani P, Hempen PM, Jones J, Kern SE: The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Res 2002, 62:5351-5357.
35. Lindsay CK, Thorgerisson UP, Tsuda H, Hirohashi S: Expression of tissue inhibitor of metalloproteinase-1 and type IV collagenase/gelatinase messenger RNAs in human breast cancer. Hum Pathol 1997, 28:359-366.
36. Zhang F, Riley J, Gant TW: Intrinsic multidrug class 1 and 2 gene expression and localization in rat and human mammary tumors. Lab Invest 1996, 75:413-426.
37. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC: Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113:1318-1327.
38. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:727-741.
39. Chen B, Nelson DM, Sadovsky Y: N-myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury. J Biol Chem 2006, 281:2764-2772.
40. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles TL, Ilsenbeck S, Wong H, Osborne CK, O’Connell P, Chang JC: Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat 2006, 95:229-233.